Replies to post #4970055 on BB's Stock Haven

[stock1ace1]

Cing .79 pending news licensing partnership news & NDA for there phase 3 adhd drug


-> 3 Million Float / 6 Mill o/s

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

“”We also believe this communication provides additional go-to-market momentum as we continue to meet with potential partners for the outlicensing of CTx-1301 in the United States and abroad.

[stock1ace1]

Cing .82s up breakout watch